0.00
전일 마감가:
$93.80
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$80.00M
수익:
-
순이익/손실:
$-75.52M
주가수익비율:
0.00
EPS:
-2.88
순현금흐름:
$-56.92M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
명칭
Aerovate Therapeutics Inc
전화
617-443-2400
주소
930 WINTER STREET, WALTHAM
AVTE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
AVTE
Aerovate Therapeutics Inc
|
0.00 | 80.00M | 0 | -75.52M | -56.92M | -2.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-14 | 개시 | Jefferies | Buy |
2025-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
2025-05-07 | 개시 | Wedbush | Outperform |
2025-05-05 | 개시 | Stifel | Buy |
2025-05-02 | 개시 | TD Cowen | Buy |
2024-06-18 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2024-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2024-06-17 | 다운그레이드 | BTIG Research | Buy → Neutral |
2024-06-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-06-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
2024-03-25 | 재개 | Jefferies | Buy |
2023-12-08 | 개시 | Wells Fargo | Equal Weight |
2023-03-01 | 개시 | Guggenheim | Buy |
2022-12-06 | 업그레이드 | BTIG Research | Neutral → Buy |
2022-09-19 | 재개 | Wedbush | Outperform |
2022-08-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
2022-02-11 | 개시 | BTIG Research | Buy |
2021-07-26 | 개시 | Cowen | Outperform |
2021-07-26 | 개시 | Evercore ISI | Outperform |
2021-07-26 | 개시 | Jefferies | Buy |
2021-07-26 | 개시 | Wedbush | Outperform |
모두보기
Aerovate Therapeutics Inc 주식(AVTE)의 최신 뉴스
Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 2.3% – Still a Buy? - Defense World
Aerovate Therapeutics (AVTE) Projected to Post Earnings on Monday - Defense World
Rhumbline Advisers Acquires 9,154 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Deep Track Capital, LP Acquires New Holdings in Aerovate Therapeutics Inc - GuruFocus
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded to Buy at Guggenheim - Defense World
Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 - MarketScreener
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation - Investing.com Canada
Aerovate Therapeutics (NASDAQ:JBIO) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Millennium Management LLC Cuts Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
FMR LLC's Strategic Acquisition of Aerovate Therapeutics Inc Shares - GuruFocus
19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC - Defense World
Bank of America Corp DE Has $612,000 Stock Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Investments LP Cuts Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Two Sigma Advisers LP Grows Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Northern Trust Corp Purchases 6,296 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
BNP Paribas Financial Markets Makes New Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Aerovate Therapeutics (AVTE) to Release Earnings on Monday - Defense World
Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences - marketscreener.com
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
Aerovate Therapeutics Announces Range Of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Aerovate Therapeutics Inc (AVTE)’s financial ratios: A comprehensive overview - DWinneX
JBIO Stock Price and Chart — NASDAQ:JBIO - TradingView
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE St - GuruFocus
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE Stock News - GuruFocus
Jade Biosciences merges with Aerovate Therapeutics07:00:02 29 Apr 2025RTW News article - London Stock Exchange
Traders Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Jade Biosciences closes merger with Aerovate Therapeutics - Coast Reporter
Aerovate Therapeutics Inc (AVTE) gets rating Downgrade from Wells Fargo - knoxdaily.com
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million - Benzinga
Russell Investments Group Ltd. Boosts Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics Inc (AVTE) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Aerovate Therapeutics (AVTE) Soars 721.88% on Merger, Dividend News - AInvest
AVTE’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) - Barchart.com
AVTE Shares Experience Decline in Value - knoxdaily.com
Aerovate Therapeutics Inc (AVTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):